Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Nanobiotix - Revenue for the second quarter of 2013

Abstract:
NANOBIOTIX (Euronext : NANO - ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces its revenue for the second quarter of 2013.

Nanobiotix - Revenue for the second quarter of 2013

Paris, France | Posted on July 13th, 2013

Income statement



in €


Q2 2013*


H1 2013

Revenue

of which :

License

Services

48,569

45,847

2,722

95,050

93,328

2,722

*over the second quarter of 2012, the company recorded no revenue

Activity

As in previous quarters, revenue recorded during the second quarter of 2013 corresponds to the pro rata share of the first payment received by the company within the framework of the licensing contract signed with PharmaEngine, the Taiwan-based biopharmaceutical company, in August 2012, which covers the development and commercialization of NBTXR3 in the Asia-Pacific region. This upfront payment amounts to €810,640, generating a product of €45,847 for the period and totalling €92,328 for the first semester in 2013. The invoicing of services totalled €2,722 for the period. In total, revenue for the second quarter amounts €48,569. Revenue for the first half of 2013 is €95,050 which is fully in line with Company expectations.

Nanobiotix remains focused on the clinical development of its lead products where commercialization is planned for 2017. Recent positive news flow, especially in June, indicates the successful implementation of Nanobiotix's strategy in line with the Company's development plan. In June, Nanobiotix published encouraging preliminary results for lead product NBTXR3 with clinical proof of concept, safety and security of the intratumoral injection in patients with soft tissue sarcoma. In parallel, Nanobiotix has received approval from ANSM to start a new clinical trial for NBTXR3 in head and neck cancer patients, a major concern in terms of public health in European countries and across Asia. Nanobiotix has also initiated the preclinical development of NBTX-IV, the second product from the NanoXray pipeline, through collaboration with the US National Cancer Institute (NCI).

Financial calendar

Results for the first half of 2013, on August 30, 2013

####

About Nanobiotix
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product, NBTXR3 based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.

Nanobiotix is listed on the regulated market of NYSE Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP).

For more information, please click here

Contacts:
Nanobiotix

Laurent Levy
CEO
+33 (0)1 40 26 07 55


NewCap.
Financial communication
and investors relations
Louis-Victor Delouvrier
Emmanuel Huynh
+33 (0)1 44 71 98 53


Yucatan
Media relations (France)
Annie-Florence Loyer
Nadège Le Lezec
+33 (0)1 53 63 27 27
+33 (0)6 88 20 35 59


College Hill
Media relations (Outside France)
Melanie Toyne Sewell
Claire Dickinson
Donia Al Saffar
+44 (0) 207 457 2020

Copyright © Nanobiotix

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

How to maximize the superconducting critical temperature in a molecular superconductor: International team led by Tohoku University opens new route for discovering high Tc superconductors April 19th, 2015

Engineer improves rechargeable batteries with MoS2 nano 'sandwich' April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Govt.-Legislation/Regulation/Funding/Policy

Engineer improves rechargeable batteries with MoS2 nano 'sandwich' April 18th, 2015

New Biological Nano-Fertilizers Presented in Iran as Appropriate Replacements for Chemical Fertilizers April 18th, 2015

Beyond the lithium ion -- a significant step toward a better performing battery April 18th, 2015

Oxford Instruments commissions high field outsert magnet system for the National High Magnetic Field Laboratory 32 Tesla magnet program April 17th, 2015

Nanomedicine

Optical resonance-based biosensors designed for medical applications April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Novel nanoparticles could save soldiers' lives after explosions April 15th, 2015

Nanoparticles at specific temperature stimulate antitumor response: Dartmouth researchers identify precise heat to boost immune system against cancer tumors April 14th, 2015

Announcements

How to maximize the superconducting critical temperature in a molecular superconductor: International team led by Tohoku University opens new route for discovering high Tc superconductors April 19th, 2015

Iranian Foodstuff, Agricultural Industries Welcome Nanotechnology Packaging Bags April 18th, 2015

Nanocomposites Play Effective Role in Production of Smart Fibers April 18th, 2015

Dais Analytic Corporation Appoints Eliza Wang to Board of Directors: Company's Newest Director Brings Expertise in Commercial and Legal Matters Both in the United States and China; Joins on the Heels of Successful Business Development Trade Mission to China April 18th, 2015

Financial Reports

Harris & Harris Group Reports Financial Statements as of December 31, 2014 and Posts Annual Letter to Shareholders on Website March 17th, 2015

Aspen Aerogels, Inc. Schedules Fourth Quarter and Fiscal 2014 Earnings Release and Conference Call for February 26, 2015 February 11th, 2015

Arrowhead to Report Fiscal 2015 First Quarter Financial Results February 2nd, 2015

Graphenea sales more than double in 2014 January 29th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE